Grifols (GIKLY) Change in Working Capital (2010 - 2020)
Grifols (GIKLY) posted Change in Working Capital of -$66.3 million for Q1 2020, down 226.55% quarter-over-quarter from $52.4 million in Q4 2019, and down 90.98% year-on-year from -$735.3 million in Q2 2019.
Grifols (GIKLY) Change in Working Capital (2010 - 2020) Analysis & Trends
Grifols (GIKLY) has reported Change in Working Capital for 10 consecutive years, with -$66.3 million the latest figure, recorded in Q1 2020.
- Change in Working Capital for Q1 2020 came in at -$66.3 million, down 90.98% year-over-year; the trailing twelve-month figure through Mar 2020 was -$50.8 million (down 180.44% YoY), and the FY2025 annual result was $36.1 million, down 95.46% from the prior year.
- Change in Working Capital was -$66.3 million for Q1 2020 at Grifols, down from $52.4 million in the prior quarter.
- Over five years, Change in Working Capital peaked at $179.9 million in Q2 2017 and troughed at -$66.3 million in Q1 2020.
- Average Change in Working Capital over 5 years is $34.0 million, with a median of $43.0 million recorded in 2016.
- The widest YoY moves for Change in Working Capital: up 2571.89% in 2019, down 391.37% in 2019.
- Over 5 years, Change in Working Capital stood at $52.9 million in 2016, then jumped by 34.75% to $71.3 million in 2017, then sank by 102.97% to -$2.1 million in 2018, then soared by 2571.89% to $52.4 million in 2019, then plunged by 226.55% to -$66.3 million in 2020.
- Per Business Quant data, the three most recent Change in Working Capital figures were -$66.3 million in Q1 2020, $52.4 million in Q4 2019, and -$34.7 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Working Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.51 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -787.00 Mn |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -66.31 Mn |
| Mar 31, 2020 | -66.31 Mn |
| Dec 31, 2019 | 52.39 Mn |
| Dec 31, 2019 | 52.39 Mn |
| Mar 31, 2019 | -34.72 Mn |
| Mar 31, 2019 | -34.72 Mn |
| Dec 31, 2018 | -2.12 Mn |
| Dec 31, 2018 | -2.12 Mn |
| Jun 30, 2018 | 88.02 Mn |
| Jun 30, 2018 | 88.02 Mn |
| Mar 31, 2018 | 11.92 Mn |
| Mar 31, 2018 | 11.92 Mn |
| Dec 31, 2017 | 71.33 Mn |
| Dec 31, 2017 | 71.33 Mn |
| Jun 30, 2017 | 179.86 Mn |
| Jun 30, 2017 | 179.86 Mn |
| Mar 31, 2017 | -22.48 Mn |
| Mar 31, 2017 | -22.48 Mn |
| Dec 31, 2016 | 52.93 Mn |
| Dec 31, 2016 | 52.93 Mn |